Healthy Upside Potential: Caredx Inc (CDNA)

With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.98 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $10.71 whereas the lowest price it dropped to was $10.07. The 52-week range on CDNA shows that it touched its highest point at $12.93 and its lowest point at $4.80 during that stretch. It currently has a 1-year price target of $12.40. Beta for the stock currently stands at 1.42.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDNA was up-trending over the past week, with a rise of 8.18%, but this was down by -3.01% over a month. Three-month performance dropped to -19.75% while six-month performance rose 46.59%. The stock gained 13.41% in the past year, while it has lost -14.00% so far this year. A look at the trailing 12-month EPS for CDNA yields -3.55 with Next year EPS estimates of -1.32. For the next quarter, that number is -0.47. This implies an EPS growth rate of 55.36% for this year and 16.67% for next year. EPS is expected to grow by 20.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.96%.

Float and Shares Shorts:

At present, 51.50 million CDNA shares are outstanding with a float of 49.43 million shares on hand for trading. On Mar 15, 2024, short shares totaled 4.36 million, which was 8.42% higher than short shares on Feb 15, 2024. In addition to Mr. Abhishek Jain as the firm’s CFO & Principal Accounting Officer, Dr. Peter Maag Ph.D. serves as its Executive Director.

Institutional Ownership:

Through their ownership of 100.39% of CDNA’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDNA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, CDNA has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CDNA currently yields $0.00. In the past year, CDNA’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CDNA has a current buyback yield of $5.15. This was $5.15 for the TTM, and it was $– for the past five years.